References
- Paper of special note have been highlighted as:
- * of interest
- ** of considerable interest
- Halban PA, Polonsky KS, Bowden DW, et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care. 2014;37:1751–1758.
* Article provided an overview of pancreatic β-cell failure.
- Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science. 2005;307:380–384.
** Article provided an overview of pathogenesis of type 2 diabetes.
- Kaneto H, Matsuoka T. Role of pancreatic transcription factors in maintenance of mature β-cell function. Int J Mol Sci. 2015;16:6281–6297.
- Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004;279:42351–42354.
- Ahlgren U, Jonsson J, Jonsson L, et al. β-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the β-cell phenotype and maturity onset diabetes. Genes Dev. 1998;12:1763–1768.
- Holland AM, Hale MA, Kagami H, et al. Experimental control of pancreatic development and maintenance. Proc Natl Acad Sci USA. 2002;99:12236–12241.
- Wang H, Brun T, Kataoka K, et al. MAFA controls genes implicated in insulin biosynthesis and secretion. Diabetologia. 2007;50:348–358.
- Zhang C, Moriguchi T, Kajihara M, et al. MafA is a key regulator of glucose-stimulated insulin secretion. Mol Cell Biol. 2005;25:4969–4976.
- Matsuoka T, Kaneto H, Miyatsuka T, et al. Regulation of MafA expression in pancreatic β-cells in db/db mice with diabetes. Diabetes. 2010;59:1709–1720.
- Hang Y, Yamamoto T, Benniger RK, et al. The MafA transcription factor becomes essential to islet β-cells soon after birth. Diabetes. 2014;63:1994–2005.
- Nishimura W, Takahashi S, Yasuda K. MafA is critical for maintenance of the mature beta cell phenotype in mice. Diabetologia. 2015;58:566–574.
- Matsuoka T, Kaneto H, Kawashima S, et al. Preserving MafA expression in diabetic islet β-cells improves glycemic control in vivo. J Biol Chem. 2015;290:7647–7657.
- Harmon JS, Bogdani M, Parazolli SD, et al. ß-cell specific overexpression of glutathione peroxidase preserves intranuclear MafA and reverses diabetes in db/db mice. Endocrinology. 2009;150:4855–4862.
- Mahadevan J, Parazzoli S, Oseid E, et al. Ebselen treatment prevents islet apoptosis, maintains intranuclearPdx-1 and MafA levels, and preserves β-cell mass and function in ZDF rats. Diabetes. 2013;62:3582–3588.
- Ristow M. Unraveling the truth about antioxidants: mitohormesis explains ROS-induced health benefits. Nat Med. 2014;20:709–711.
- Birringer M, Kuhlow D, Pfluger PT, et al. Improved glucose metabolism in mice lacking alpha-tocopherol transfer protein. Eur J Nutr. 2007;46:397–405.
- Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to the impaired incretin effects in diabetes. Diabetes. 2007;56:1551–1558.
- Kawashima S, Matsuoka T, Kaneto H, et al. Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice. Biochem Biophys Res Commun. 2011;404:534–540.
- Shu L, Matveyenko AV, Kerr-Conte J, et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet. 2009;18:2388–2399.
- Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006;355:241–250.
- Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem. 2008;283:8723–8735.
- Takamoto I, Kubota N, Nakaya K, et al. TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass. Diabetologia. 2014;57:542–553.
- Mitchell RK, Mondragon A, Chen L, et al. Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass. Hum Mol Genet. 2015;24:1390–1399.